Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives

Journal of Medicinal Chemistry

Volumn 42, Issue 10, 1999, Pages 1816-1822

  Moreau, Pascale ^a   Anizon, Fabrice ^a   Sancelme, Martine ^a   Prudhomme, Michelle ^a   Sevère, Danièle ^b   Riou, Jean François ^b   Goossens, Jean François ^c   Hénichart, Jean Pierre ^c   Bailly, Christian ^d   Labourier, Emmanuel ^e   Tazzi, Jamal ^e   Fabbro, Doriano ^f   Meyer, Thomas ^f   Aubertin, A M ^g  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b SANOFI   (France)

^c UNIV LILLE   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^f NOVARTIS PHARMA AG   (Switzerland)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROMINE DERIVATIVE; CAMPTOTHECIN; DNA TOPOISOMERASE; PROTEIN KINASE C; REBECCAMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CROSS LINKING; CYTOTOXICITY; DNA BINDING; DNA CLEAVAGE; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; GRAM POSITIVE BACTERIUM; LEUKEMIA CELL; STRUCTURE ACTIVITY RELATION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; BACILLUS CEREUS; CARBAZOLES; CATTLE; DNA; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; GLUCOSE; INDOLES; INHIBITORY CONCENTRATION 50; PHOSPHOTRANSFERASES; PROTEIN KINASE C; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033587125     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980702n     Document Type: Article

References (30)

1. Froelich-Ammon, S. J.; Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 1995, 270, 21429-21432.
2. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692.
3. D'Arpa, P.; Liu, L. F. Topoisomerase targeting antitumor drugs. Biochim. Biophys. Acta 1989, 989, 1-9.
4. Rothenberg, M. L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 1997, 8, 837-855.
5. Hertzberg, R. P.; Carafanda, M. J.; Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28, 4629-4638.
6. Labourier, E.; Rossi, F.; Gallouzi, I.-E.; Allemand, E.; Divita, G.; Tazi, J. Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor. Nucleic Acids Res. 1998, 26, 2955-2962.
7. Rossi, F.; Labourier, E.; Forné, T.; Divita, G.; Derancourt, J.; Riou, J.-F.; Antoine, E.; Cathala, G.; Brunel, C.; Tazi, J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996, 381, 80-82.
8. Rossi, F.; Labourier, E.; Gallouzi, I.-E.; Derancourt, J.; Allemand, E.; Divita, G.; Tazi, J. The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity. Nucleic Acids Res. 1998, 26, 2963-2970.
9. Tazi, J.; Rossi, F.; Labourier, E.; Gallouzi, I.-E.; Brunel, C.; Antoine, E. DNA topoisomerase I: a custom-officer at DNA-RNA worlds border? J. Mol. Med. 1987, 75, 786-800.
10. Macdonald, J. S.; Benedetti, J. K.; Modiano, M.; Alberts, D. S. Phase II evaluation of topotecan in patients with advanced colorectal cancer. Invest. New Drugs 1997, 15, 357-359.
11. Wiseman, L. R.; Markham, A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drug Eval. 1996, 52, 606-623.
12. Nettleton, D. E.; Doyle, T. W.; Krishnan, B.; Matsumoto, G. K.; Clardy, J. Isolation and structure of rebeccamycin: a new antibiotic from Nocardia aerocolonigenes. Tetrahedron Lett. 1986, 26, 4011-4014.
13. Bush, J. A.; Long, B. H.; Catino, J. J.; Bradner, W. T.; Tomita, K. Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiot. 1987, 40, 668-678.
14. Yoshinari, T.; Matsumoto, M.; Arakawa, H.; Okada, H.; Noguchi, K.; Suda, H.; Okura, A.; Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB506): Induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 1995, 55, 1310-1315.
15. Cleary, J.; Tutsch, K. D.; Berlin, J.; Arzoomanian, R. Z.; Alberti, D.; Feierabend, C.; Simon, K.; Hutson, P.; Stewart, J.; Wilding, G. Phase I clinical and pharmacokinetic study of rebeccamycin analogue (NCS 655649). Proc. Am. Assoc. Cancer Res. 1996, 37, 164.
16. Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Carrasco, C.; Ollier, M.; Sevère, D.; Riou, J. P.; Fabbro, D.; Meyer, T.; Aubertin, A. M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. 1998, 41, 1631-1640.
17. Rodrigues Pereira, E.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, M.; Sevère, D.; Riou, J. F.; Fabbro, D.; Meyer, T. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem. 1996, 39, 4471-4477.
18. Anizon, F.; Belin, L.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Sevère, D.; Riou, J. F.; Bailly, C.; Fabbro, D.; Meyer, T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 1997, 40, 3456-3465.
19. Kaneko, T.; Wong, H.; Utzig, J.; Schurig, J.; Doyle, T. W. Water soluble derivatives of rebeccamycin. J. Antibiot. 1990, 43, 125-127.
20. Bailly, C.; Riou, J. F.; Colson, P.; Houssier, C.; Rodrigues Pereira, E.; Prudhomme, M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamyein. Biochemistry 1997, 36, 3917-3929.
21. Baker, B. F.; Dervan, P. B. Sequence-specific cleavage of DNA by N-bromoacetyldistamycin. Product and kinetic analyses. J. Am. Chem. Soc. 1989, 111, 2700-2712.
22. Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Sevère, D.; Riou, J. F.; Fabbro, D.; Meyer, T.; Aubertin, A. M. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem. 1999, 42, 584-592.
23. Kotzyba-Hibert, F.; Kapfer, I.; Goldner, M. Recent trends in photoaffinity labeling. Angew. Chem., Int. Ed. Engl. 1995, 34, 1296-1312.
24. Wick, K. L.; Matthews, K. S. Interaction between lac repressor protein and site-specific bromodeoxyuridine-substituted operator DNA. J. Biol. Chem. 1991, 266, 6106-6112.
25. Brenner, M.; Rexhausen, H.; Steffan, B.; Steglich, W. Synthesis of arcyriarubin B and related bisindolylmaleimides. Tetrahedron 1988, 44, 2887-2892.
26. 2+ dependent protein kinase. Biochem. Biophys. Res. Commun. 1986, 135, 397-402.
27. Takahashi, I.; Kobayashi, E.; Asano, K.; Yoshida, M.; Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot. 1987, 40, 1782-1784.
28. Zahler, A. M.; Lane, W. S.; Stolk, J. A.; Roth, M. B. SR proteins: a conserved family of pre-mRNA splicing factors. Genes Dev. 1992, 6, 837-847.
29. Labourier, E.; Riou, J.-F.; Prudhomme, M.; Carrasco, C.; Bailly, C.; Tazi, J. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and inhibition of the protein kinase activity. Cancer Res. 1999, 59, 52-55.
30. Goossens, J.-F.; Dassonneville, L.; Facompré, M.; Hénichart, J.-P.; Dugave, C.; Prudhomme, M.; Bailly, C. Cellular uptake and interaction with purified membranes of indolocarbazole derivatives of rebeccamycin. Influence of the sugar moiety. Manuscript in preparation.